GET DAILY SIGNALSAstraZeneca (AZN) Earnings Preview: Growth Momentum Meets High Expectations
Key Takeaways
-
Q4 2025 estimates: Revenue ~$15.7B, EPS $2.18, reflecting continued 9M growth.
-
Full-year guidance: Total revenue expected to grow high single digits (CER); 9M revenue already up 11%.
-
Core EPS: Low double-digit growth guidance, following 15% increase to $7.04 in first nine months.
-
Drivers: Oncology blockbusters Tagrisso and Imfinzi, and CVRM therapy Farxiga, sustaining momentum.
-
Investor focus: Pipeline readouts, 2026 guidance, and emerging market demand.
-
Market reaction: Q3 beat in November 2025 lifted shares 4.6%, highlighting positive sentiment.
Earnings Context
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
-
Oncology leadership and pipeline execution
-
CVRM resilience and rare disease expansion
-
Margin trends, U.S. manufacturing investments, and patent cliff mitigation
For investors, Q4 results provide clarity on execution, operational leverage, and mid-teens growth potential through 2030.
Q4 2025 Expectations
-
Revenue: ~$15.7B, up from prior year
-
EPS: $2.18 consensus
-
Full-year: $58–59B total revenue (high single-digit CER growth), low double-digit core EPS growth
Key focus areas:
-
Oncology revenue: +16% YTD to $18.6B, driven by Tagrisso and Imfinzi
-
CVRM growth: Farxiga up 11% YTD
-
Rare disease: Ultomiris expansion offsets Soliris decline
Historical beats, like Q3’s $15.2B revenue and $2.38 core EPS, indicate potential upside, though currency volatility remains a consideration.
Market Sentiment & Technical Perspective
Post-Q3, investors are cautiously optimistic. Analysts highlight strong oncology demand and reaffirmed guidance, while risks include U.S. pricing pressures and regulatory scrutiny in China. Historical post-earnings moves average ~1.8% upward, with option flows and institutional positioning suggesting measured confidence.
AI trading tools: Trend Trader for Beginners: Strategy for Large Cap Stocks, 60 min, (TA) identifies short- to medium-term trends for large-cap pharma like AZN, emphasizing low-risk entries and capturing post-earnings momentum. Backtested success rates exceed 60% for similar scenarios.
Forward Outlook
Post-Q4, focus turns to 2026 guidance and pipeline execution:
-
Revenue growth expected in the high teens, supported by $50B U.S. investment in manufacturing and R&D
-
16 Phase III readouts in 9M 2025 drive approvals for Enhertu, Imfinzi, and Truqap
-
Therapy area dynamics:
-
Oncology: Tagrisso $5.4B sales, competitive landscape
-
CVRM: Farxiga +11%, SGLT2 margins under watch
-
Rare disease: Ultomiris expansion offsetting Soliris decline
-
Additional factors: Core tax rate 18–22%, forex impacts, emerging market demand, and regulatory progress on baxdrostat and datopotamab deruxtecan. Balanced execution across these areas supports AZN’s growth trajectory toward 2030, with pipeline success and loss-of-exclusivity mitigation critical to sustained performance.
Disclaimers and Limitations
AZN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AZN turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 27 of 42 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 50 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.749) is normal, around the industry mean (-1.360). P/E Ratio (27.660) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement